Metformin exerted an anti-angiogenic effect in breast cancer models by inhibitiHER2-mediated VEGF upregulation and HIF-1α-mediated VEGF up-regulation, suggesting a novel mechanism of metformin targeting the HER2/HIF-1α/VEGF signaling axis (Wang et al., 2015). Here, HIF1A is linked to breast cancer.